Powered by RND
PodcastsHealth & WellnessThe Peptide Podcast

The Peptide Podcast

The Peptide Queen
The Peptide Podcast
Latest episode

Available Episodes

5 of 163
  • Finding the Right Fit: Semaglutide, Tirzepatide, or Retatrutide
    Today, we're tackling a question that comes up often in peptide, weight loss, and nutrition clinics: why does one person see great results with semaglutide, while another responds better to tirzepatide—or even retatrutide? If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ All three peptides target the incretin system, but they act in slightly different ways—and those differences can dramatically affect outcomes. Let's start with the basics. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the gut hormone GLP-1, which increases insulin when blood sugar is high (to help lower blood sugar), suppresses glucagon (which also decreases blood sugar), and slows gastric emptying. It also enhances satiety—so you feel full longer and eat less. Tirzepatide is a dual agonist, acting on both GLP-1 and GIP receptors. GIP—glucose-dependent insulinotropic polypeptide—also helps with insulin secretion to lower blood sugar, increases fat metabolism, and may reduce some of the GI side effects seen with GLP-1 alone. Retatrutide, the newest in the lineup, is a triple agonist that targets GLP-1, GIP, and glucagon receptors. Retatrutide lightly activates the glucagon receptor while strongly activating GLP-1 and GIP receptors, which help regulate blood sugar and boost insulin secretion. This keeps blood sugar stable—or even improves it. Beyond blood sugar, glucagon also ramps up metabolism and calorie burning. By gently engaging glucagon receptors, retatrutide can increase energy expenditure and support fat loss without triggering large blood sugar spikes. So how do you decide which one might work best? Let's walk through common clinical situations. Patients with Hypothyroidism Let's talk about hypothyroidism. People with hypothyroidism often have slower metabolism, making weight loss more difficult even with a balanced diet. Low thyroid hormone levels slow calorie burning and energy use, so weight gain can occur more easily. For these patients, semaglutide is a reliable starting point—it helps regulate appetite and caloric intake. If progress plateaus, tirzepatide or retatrutide may provide an edge by boosting energy expenditure and fat oxidation, essentially "jump-starting" a slower metabolism. Patients with PCOS (Polycystic Ovary Syndrome) What about patients with PCOS (polycystic ovary syndrome)? Insulin resistance is common in PCOS, often leading to higher androgen levels (e.g., testosterone) and symptoms like irregular periods, acne, and excess hair growth. Hormonal changes also affect appetite-regulating hormones, increasing hunger and cravings. Both GLP-1 and dual agonists have proven effective in managing metabolic and reproductive aspects of PCOS. Typically, we start with semaglutide to improve weight, insulin sensitivity, androgen levels, and menstrual regularity. After a few months, if weight loss plateaus or cravings remain high, we may switch to tirzepatide. The added GIP activity enhances fat metabolism, insulin control, and may further support hormone regulation and ovulation. The key is starting with what's well-studied and tolerated, then stepping up if additional metabolic or reproductive support is needed. Type 2 Diabetes (T2DM) The next medical condition I'd like to talk about is type 2 diabetes (T2DM). Weight gain in T2DM often stems from insulin resistance. Cells don't respond effectively to insulin, prompting the pancreas to relelase more. High insulin levels encourage fat storage, particularly around the abdomen, while elevated blood sugar can increase hunger and cravings. Some diabetes medications, like insulin or sulfonylureas (e.g., glipizide or glyburide), can also contribute to weight gain. All three drugs lower blood sugar and promote weight loss, but tirzepatide currently shows the strongest combined A1c reduction (average blood sugar over the past 2 to 3 months) and weight loss. GIP and GLP-1 work together to enhance insulin response more effectively than GLP-1 alone. Retatrutide is in phase 3 trials, with potential FDA approval as early as 2027. Its glucagon receptor activity may offer additional glucose regulation and energy expenditure benefits. Patients with >15% Weight Loss Goals Okay, let's talk about weight loss goals and how this ties into the decision process for choosing a weight loss medication. For those patients looking to lose more than 15% of their total body weight, tirzepatide or retatrutide are likely to deliver greater results. Clinical data show semaglutide can achieve up to 15% total weight loss while tirzepatide can achieve up to 22% and retatrutide up to 24%. That said, semaglutide remains a highly effective option for weight loss. However, if progress begins to plateau, transitioning to a dual or triple agonist may help restart weight loss and push past that plateau. Pre- and Postmenopausal Women What about peri- and postmenopausal patients? Hormonal shifts during perimenopause and menopause slow metabolism and can increase cravings. Declining estrogen promotes abdominal fat storage and affects appetite-regulating hormones. Semaglutide helps with appetite control and gradual fat loss, while tirzepatide's GIP activation can further support fat metabolism when estrogen levels drop. Patients with Heart Disease or High Cholesterol The last group of patients I'd like to discuss is patients with heart disease (e.g., heart failure, stroke, heart attack, or even atherosclerosis) or people with high cholesterol. Semaglutide has the strongest cardiovascular outcomes data, reducing major adverse cardiac events by 20% and improving LDL cholesterol (bad cholesterol) and blood pressure. Tirzepatide shows promise for heart and lipid benefits, but those trials are still ongoing. For patients with prior heart attack, stroke, or severe coronary artery disease, semaglutide remains the safest evidence-backed starting point—unless intolerable side effects or weight loss resistance occur. Tolerability Now I want to switch gears a bit and talk about side effects and tolerablity of these peptides. Some patients experience stomach-related side effects like nausea, bloating, or acid reflux on semaglutide. Generally, tirzepatide tends to cause fewer GI side effects, likely due to GIP balancing GLP-1 activity in the gut. So patients struggling with nausea or other stomach-related side effects may find tirzepatide more tolerable. Just something to keep in mind. Individualizing Therapy Lastly, I want to highlight the importance of individualizing weight loss peptide treatments. There's no one-size-fits-all approach when it comes to these therapies. Clinicians should carefully consider a patient's goals, medical history, current medications, and tolerance before choosing the most appropriate option. Setting realistic expectations from the start is essential. It's important to remember that everyone's body responds differently because of factors like hormones, genetics, metabolism, gut microbiome balance, and lifestyle habits. These differences influence how effectively a peptide therapy works and how well it's tolerated. That's why ongoing monitoring and follow-up are such an important part of the process. Providers track progress, adjust dosing when needed, and switch medications if weight loss plateaus or side effects occur. The goal isn't just to lose weight quickly—it's to create a safe, sustainable plan that supports long-term metabolic health and helps patients feel their best. Thanks for listening to The Peptide Podcast.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Until next time, be well, and have a happy, healthy week.
    --------  
    12:47
  • GLP-1's & Addiction
    Today we're talking about peptides being researched for addiction. We'll unpack the science behind the incretin system, how those pathways tie into reward and substance use, and focus in on the newest triple‐agonist retatrutide. We'll also look at early evidence for alcohol, tobacco and other substance-use disorders when using certain peptide therapies. If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ What are GLP-1, GIP and the "dual/triple" agonists? First, let's review some biology to ground the discussion. GLP-1 (glucagon‐like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin hormones. Incretins are gut hormones that help with digestion and blood sugar control. They're released by the gut in response to food.  GLP-1 raises insulin levels after you eat to help lower blood sugar, slows gastric emptying, and reduces appetite. It also reduces how much glucagon your body makes. This helps to lower your blood sugar. Medications like semaglutide and dulaglutide work by mimicking GLP-1 and are often referred to as "GLP-1 agonists". GIP has somewhat overlapping but distinct roles from GLP-1. It too, influences insulin secretion, but it also helps with fat metabolism.  In a nut shell, GIP helps fat cells respond more efficiently to insulin so they release stored fat to be used as energy when your body needs it. This process helps your metabolism shift from just storing energy to burning fat for fuel. Medications like tirzepatide work by mimicking both GLP-1 and GIP and are often referred to as "dual" agonists.  When GIP and GLP-1 are activated together — like in tirzepatide — they work as a team: GLP-1 helps control appetite and slow down digestion. GIP boosts how your body handles insulin and energy. Together, they help reduce hunger, improve metabolism, and burn fat more efficiently. Now here's where it gets a bit tricky.  A newer medication that's still in development, retatrutide, works on three hormone pathways: GLP-1, GIP, and glucagon receptors. It's called a "triple agonist", and even though it activates the glucagon receptor, it doesn't cause high blood sugar like you might expect. It's about balance. In type 2 diabetes and obesity, the body's hormone signals are out of balance. Retatrutide gently activates the glucagon receptor, but at the same time it strongly activates GLP-1 and GIP receptors — which still help control blood sugar and increase insulin. So blood sugar stays stable or even improves overall. Glucagon doesn't just affect blood sugar — it also increases metabolism and helps the body burn fat and calories. By slightly stimulating glucagon receptors, retatrutide can boost energy use and promote fat loss without causing big spikes in blood sugar. As a result, you get the blood sugar control of GLP-1 and GIP, plus the fat-burning benefits of glucagon activation — leading to even greater weight loss and metabolic improvement.  Right now, retatrutide is in phase 3 clinical trials, which are the final stage of testing before approval. These studies are expected to finish in early 2026, and if results look good, the FDA could approve retatrutide as early as 2027.  Addiction Why is this relevant for addiction? Because the gut-brain axis, reward circuitry, and the pathways that regulate "wanting/consuming" food overlap with those involved in substance use.  Appetite, reward, and craving may share neural substrates (dopamine, GABA, mesolimbic system) and so a drug that reduces drive to eat might also modulate drive to drink, smoke or use other substances. The link between GLP-1/related drugs and substance use disorders  Let's now dive into what the research says about GLP-1 receptor agonists (and related medications) in the context of alcohol, tobacco, and other substances. Let's start with what we know from animal research. In pre-clinical studies, scientists have found that GLP-1 receptor agonists seem to change how animals respond to addictive substances. A systematic review showed that in rodents, treatment with GLP-1 drugs reduced the behavioral effects of alcohol, nicotine, amphetamine, and cocaine. For example, one GLP-1 drug called exendin-4 reduced alcohol-related behaviors in rodents. And even more recently, a study in both male and female rats showed that giving semaglutide, tirzepatide, or even retatrutide, reduced alcohol discrimination, meaning the rats didn't experience the same "feeling" from alcohol as before. This means that the "interoceptive stimulus effects" or the internal sensations — how alcohol feels inside the body, changed. This is really important because this is what often drives people to drink or relapse. So, if these medications can blunt those internal cues, it suggests they might disrupt the rewarding effects of alcohol that help maintain addiction. When we shift to human studies, things get even more interesting. A systemic review found that out of five studies looking at GLP-1 receptor agonists in people with substance use disorders — mostly alcohol and nicotine — three showed real reductions in substance use, while two did not. In one large observational study of over 150 adults with obesity who drank alcohol, those who were taking semaglutide or tirzepatide for at least 30 days reported fewer drinks, fewer binge episodes, and lower overall intake compared to people not on those drugs. A phase 2 clinical trial of once-weekly semaglutide in adults with alcohol use disorder showed similar results — lower alcohol craving and some reductions in drinking behavior. There's also data from a massive registry-based study showing that people with alcohol or opioid use disorder who were prescribed GLP-1 or GIP drugs had 50% lower rates of alcohol intoxication and a 40% lower rate of opioid overdose. Still, experts are cautious — meta-analyses and reviews consistently note that the evidence, while promising, is still early and we don't yet have large, long-term randomized controlled trials. What's Going On? So, what's actually happening inside the brain and body that could explain these changes in craving and reward? How can medications originally made for diabetes and/or weight loss end up helping with addiction?" Mechanistically, GLP-1 drugs may affect the brain's reward system — especially dopamine signaling in areas like the nucleus accumbens — and reduce the "wanting" of reward substances like food or alcohol. They might also calm stress responses and make relapse cues less powerful. And there are probably some physical effects too — things like slower digestion and increased fullness, which might make it harder to physically consume large amounts of alcohol or even smoke as much. But again, many of these findings come from animal models, which don't always perfectly reflect human addiction. Most of the focus so far has been on alcohol, though there's also some early evidence that GLP-1 drugs might influence nicotine use. For substances like opioids or cocaine, the data is thinner and more mixed. Bottom line — at this stage, GLP-1 receptor agonists, and maybe even GIP/GLP-1 dual agonists, represent a really promising new direction for treating addiction — but it's still early days. We also don't yet have human addiction studies on retatrutide, pre-clinical data in rats show that, like semaglutide and tirzepatide, it too, reduces alcohol discrimination. In practical terms, if you're treating patients with obesity or diabetes who also struggle with alcohol or nicotine use, choosing a GLP-1 or dual agonist might offer an unexpected bonus — helping with cravings. It also gives us a new way to talk with patients about how metabolism, reward, and craving are all interconnected. But — and this is important — the data are still limited. Most studies are small, short, and often focus on people with obesity or metabolic disease rather than pure addiction. So, for now, it's an adjunctive idea, not a replacement for established therapies. We'll need larger randomized trials in people with substance use disorders to really understand who benefits, what doses work, and how long the effects last. Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend, please share this episode! Until next time, be well, and as always, have a happy, healthy week.
    --------  
    7:28
  • The Science of Meal Timing, Fasting, and Weight Loss
    Today, we'll examine an important debate in nutrition: whether skipping breakfast or skipping dinner is more effective for your health and metabolism. We'll unpack what the research says, how your body's internal clock affects metabolism, and why the timing of your last meal can make or break your weight loss—especially if you're on a GLP-1 medication like semaglutide, dual GIP/GLP-1 like tirzepatide, or triple agonist like retatrutide. If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ Let's get into it. Circadian Rhythms and Eating Windows Our bodies are wired to follow a circadian rhythm—a 24-hour cycle that controls hormones like melatonin, cortisol, and insulin. One key thing to understand is that your body follows the rhythm of the day. When it's light out, you're naturally wired for activity—your metabolism is active, digestion works efficiently, and your body is more sensitive to insulin. As daylight fades, melatonin levels rise, signaling it's time to slow down, rest, and prepare for sleep. Here's the kicker: melatonin doesn't just make you sleepy—it also reduces insulin sensitivity. That means when you eat late at night—say at 8 or 9pm—your body doesn't handle sugar or calories as well. Instead of using that energy, you're more likely to store it as fat. So, a meal at 5pm when it's still light out? Your body's insulin response is stronger. You burn and use more of what you eat. But a meal at 9pm in the dark? Your body's gearing up for sleep, not digestion. Calories from that meal are more likely to go into fat storage. Breakfast vs. Dinner Skipping—What the Data Says Let's talk about what the research shows when it comes to skipping breakfast versus skipping dinner. Several studies have looked at early time-restricted feeding, where you eat earlier in the day, like between 8 a.m. and 4 p.m., versus eating later, where you skip breakfast and stretch meals into the evening. One of the most cited studies, published in Cell Metabolism. The study looked at men with prediabetes who followed an early time-restricted feeding schedule for five weeks. Even though they didn't lose weight, they had significant improvements in insulin sensitivity, blood pressure, and markers of oxidative stress compared to those eating over a twelve-hour window. The takeaway? Eating earlier in the day improved metabolic function even without reducing calories. Another study found that early eaters experienced lower evening hunger and better fat oxidation, meaning their bodies were burning fat more efficiently. By contrast, those eating later in the day had higher insulin and glucose levels after meals, signaling greater insulin resistance. And more broadly, research consistently shows that eating late at night, especially after seven or eight in the evening, is linked to increased body fat and higher risks of obesity and type 2 diabetes. The reason is straightforward: insulin sensitivity drops as the day goes on, so your body is less efficient at processing glucose at night, and those late calories are more likely to be stored as fat, especially around the belly. So while skipping breakfast might be easier for some people, from a metabolic standpoint, skipping dinner—or at least finishing it earlier—tends to be more beneficial. This connects directly to why fasting works for weight loss. Fasting gives your insulin a chance to drop, which signals your body to tap into stored fat for energy. Front-loading your meals earlier in the day aligns with your body's natural rhythm: insulin sensitivity is higher, digestion is more efficient, and your body has more opportunity to burn fat overnight. People who eat earlier often report feeling more energized, less hungry in the evening, and sleeping better—all key factors in long-term weight control. Now, if you're taking medications like semaglutide, tirzepatide, or retatrutide, timing becomes even more important. These drugs slow gastric emptying, which helps you feel full longer but also means that eating a large dinner late at night can lead to bloating, nausea, heartburn, and in turn, poor sleep. Digestion naturally slows down as melatonin rises and your body prepares for sleep, so combining a late meal with slower gastric emptying can make it harder for your body to rest and burn fat overnight. A good rule is to finish your last meal two to three hours before bed, ideally around five or six in the evening. This gives your body time to digest, allows insulin levels to drop, and lets you switch into fat-burning mode. What's the counter argument? Of course, it's important to remember that meal timing isn't one-size-fits-all. While the research often favors early eating, some people naturally aren't hungry in the morning, and skipping breakfast can actually be a helpful way to stick to a fasting window.  Then there are the "night owls." Some people's circadian rhythms naturally shift later, and for them, eating later may actually align better with their biology. Forcing an early eating schedule might leave them tired, hungry, or unable to stick with it, which can actually be counterproductive for metabolic health. Research on chronotypes—the natural variations in our sleep-wake cycles—suggests that what works for a morning person might not work for someone who thrives later in the day. Practical lifestyle factors also play a role. Work schedules, family dinners, or social events can make it hard to consistently finish dinner at five or six in the evening. For some, a slightly later meal, if it's balanced and nutrient-dense, can be more sustainable over the long term than forcing an early window and ending up snacking late anyway. Finally, metabolic flexibility matters. Some people can handle a later meal without negative effects on fat storage, insulin sensitivity, or sleep, especially if the meal is lighter or focused on protein and vegetables. The bottom line is that while early eating has clear metabolic advantages for many, especially those taking weight loss medications like tirzepatide, the most important factors are consistency, total calories, and the quality of your food, not just the exact timing. So, whether you're a morning eater, a night owl, or somewhere in between, finding an approach that fits your body and lifestyle—and that you can stick to long term—is often more important than following a strict rule about skipping breakfast or dinner. Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend, please share this episode! Until next time, be well, and as always, have a happy, healthy week.
    --------  
    6:59
  • Tesamorelin Peptide Therapy
    Today, we're talking about tesamorelin, a peptide that works through the growth hormone pathway and is especially effective when it comes to targeting stubborn belly fat. If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ So, what exactly is tesamorelin? In simple terms, it's a synthetic growth hormone-releasing hormone (GHRH) analog—basically, it signals your pituitary gland to release more growth hormone (GH). Why does that matter? Because GH plays a big role in fat metabolism, especially when it comes to visceral fat, the deep fat that surrounds your organs in your abdominal region. Here's how it works: when GH levels rise, your body starts breaking down fat for energy—a process called lipolysis. Visceral fat, in particular, is very responsive to GH. Reducing this type of fat isn't just about looking better; it also improves metabolic health, boosts insulin sensitivity, and lowers inflammation, all of which support long-term health and reduce your risk of heart disease. Why not just give GH directly? Your body only produces a certain amount of GH naturally, and this declines with age. Giving exogenous GH can boost levels quickly, but it comes with higher risks like swelling, joint pain, and sometimes insulin resistance if overused.  Tesamorelin, on the other hand, stimulates your own pituitary gland to release GH naturally, which tends to be safer and more physiologic over time. That said, GH injections might be preferred in certain clinical scenarios, but for most people, tesamorelin offers a more controlled approach. What about side effects? Some common ones include joint pain, swelling, and muscle aches. These happen because GH causes fluid retention and increased tissue growth, which can put pressure on joints and muscles.  Also, tesamorelin can slightly increase blood sugar, so people with diabetes or prediabetes should be monitored carefully. But why does this happen? Since tesamorelin works by boosting your growth hormone, it can have an impact on how your body handles glucose. Growth hormone naturally makes your body a little less sensitive to insulin, which means your cells don't take up sugar as efficiently. So, some people might notice a slight rise in fasting blood sugar when they start using tesamorelin. But here's the interesting part: growth hormone also increases IGF-1, which has some insulin-like effects. In most healthy people, this helps balance things out, so blood sugar doesn't spike dramatically. But if someone already has prediabetes or type 2 diabetes, it's something to keep an eye on. The takeaway? Tesamorelin can slightly raise blood sugar, but it's usually manageable. Regular monitoring is smart, especially for anyone with a history of blood sugar issues. And compared to direct growth hormone injections, tesamorelin tends to have less of an effect on blood sugar because it stimulates your body to release GH naturally, instead of flooding your system with it. Typical dosing of tesamorelin For men, peptide therapy is often 1 mg at night to support natural GH peaks during sleep, and 1 mg in the morning before fasted cardio or exercise. Women usually do 1 mg daily. Tesamorelin can be expensive, so many people cycle it 5 days on, 2 days off to reduce cost, or just do 1 mg at night, which still supports GH production and can even improve sleep. Typically, tesamorelin is cycled for 8 weeks on, then 8 weeks off, and most people start noticing results after 4 to 6 weeks. This cycling helps manage cost, reduce potential side effects, and allows the body to maintain responsiveness to the therapy. My Final thoughts Tesamorelin is a powerful tool for targeting visceral fat and improving body composition safely through your natural GH pathways. It's not a cheap therapy, but if used strategically—especially timed with sleep or exercise—it can give great results while minimizing side effects. Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend, please share this episode! Until next time, be well, and as always, have a happy, healthy week.
    --------  
    4:40
  • GLOW Peptide Therapy
    I'm so glad you're here today because we're diving into a therapy that people are buzzing about—GLOW peptide therapy. If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ Now, you've probably heard me talk about individual peptides before, but this one's a peptide stack—a combination of three peptides that are designed to work together. And honestly, the name says it all. People who use this blend often say they recover faster, their skin looks healthier, and they just feel better overall. That's why it's called GLOW. So today, I'm going to walk you through what GLOW peptide therapy is, what's actually in it, how each of these peptides work, typical dosing, cycles, side effects, who should avoid it, and finally—I'll go through some of the most common questions people ask. The Three Peptides in GLOW GLOW therapy combines BPC-157, TB-500 or thymosin beta-4, and GHK-Cu. Each one does something unique, but when you put them together, you get this synergistic effect that's bigger than the sum of its parts. Let's start with BPC-157. This peptide is naturally derived from something we all have in our stomach lining—it's literally called the body protection compound. And the name fits. It helps protect and repair tissue, calm down inflammation, and even support gut health. A lot of people first hear about BPC-157 because athletes use it for muscle strains, tendon injuries, or joint pain. But it's also been studied for gut issues like ulcers and leaky gut. The magic is in how it helps new blood vessels form so your tissues can actually heal faster and stronger. The next thing I want to touch on is that the GLOW peptide stack sometimes lists TB-500 or Thymosin Beta-4 (TB4) as if they're interchangeable. And while they're closely related, they're not exactly the same. Both of them are best known for their role in healing and recovery. They guide cells to the site of an injury, help reduce scar tissue, improve blood flow by encouraging new blood vessel growth, and calm down excess inflammation so real healing can happen. Where they start to differ is in their scope of action. Thymosin Beta-4 is the full-length, naturally occurring peptide — the master version, if you will. Because it's the entire chain, it interacts with more pathways and has been studied in a wide range of areas: wound healing, heart repair after a heart attack, corneal healing, brain and nerve protection, even immune system regulation. TB-500, on the other hand, is a synthetic fragment of Thymosin Beta-4. It contains the "active core" that drives cell migration and blood vessel growth. That makes it very effective for tissue repair, tendon healing, wound closure, and circulation. But it doesn't have all the extra regulatory sections that give the full peptide those broader effects on the heart, brain, or immune system. What's good to know, is that in practice, most formulations use TB-500 because it's more stable (both in the body and for storage), widely available, and it's cost-effective. Some clinics may use the full Thymosin Beta-4, but that's far less common due to the cost of production. From a user perspective, both serve the same purpose in the stack: recovery, regeneration, and repair. However, TB-500 does not have all the broader effects that the full-length Thymosin Beta-4 peptide has. Think of it this way, TB-500 tends to be seen as more targeted — very good at tissue and tendon repair, wound closure, and improving circulation, but without the same wide-ranging effects on the heart, brain, or immune system that you see with the complete TB4 peptide. Okay, moving along to the last component of the GLOW peptide stack: GHK-Cu or the copper peptide. You might've already seen this one in the skincare world—creams and serums often brag about having copper peptides because they boost collagen, smooth wrinkles, and improve elasticity. But GHK-Cu is more than just cosmetic. Inside the body, it promotes wound healing, reduces inflammation, fights oxidative stress, and even supports hair regrowth. This is the peptide that really brings the "glow" to GLOW therapy. People notice their skin looks fresher and healthier, their hair feels stronger, and they just have that rejuvenated look. Now, each of these peptides—BPC-157, TB-500 or TB-4, and GHK-Cu—can be prescribed and given separately as a subcutaneous injection, and sometimes that's the right approach depending on someone's goals. But for convenience, they're often combined into a single formulation or vial, which makes daily use a lot simpler. Instead of juggling three different injections, you're working with one balanced blend that delivers the same benefits in a more streamlined way. Why Combine Them? So, why put these three together? Well, BPC-157 is like the fire extinguisher—it calms down inflammation and starts the repair process. TB-500 or TB4 is like the construction crew—it moves the right cells into place and helps the tissue heal in a well-organized way. And GHK-Cu is like the finishing touch—it strengthens the structure, adds resilience, and brings back that youthful skin and hair quality. Individually, they're great. Together, they have synergistic power. Typical GLOW Dosing Alright, let's get practical and talk about dosing for the GLOW peptide stack. For BPC-157, the sweet spot is usually somewhere between 200 and 500 micrograms a day. When it comes to TB-500, most people land in the range of about 2 to 5 milligrams per week. If the formulation uses full thymosin Beta-4 instead, the dosing is usually a little lower since it has those broader effects on things like the immune system. In that case, you might see 1 to 2 milligrams per injection a couple times a week, or sometimes smaller daily doses depending on the goal. And then there's GHK-Cu, which typically runs in the 100 to 300 microgram per day range. So while the exact numbers can shift depending on the protocol, those ranges give you a good sense of what's common in practice. For convenience, GLOW formulations that contain all three peptides usually come in a single vial with 10 milligrams each of BPC-157 and TB-500, and 50 milligrams of GHK-Cu, so you can draw your doses from one vial rather than juggling three separate injections. Of course, these are just general guidelines—the exact dose and frequency really should be tailored to your specific needs and always prescribed by your provider. Side Effects So, what about side effects? Most people tolerate these peptides really well, but there are a few things to know. The most common side effect is some redness, irritation, or swelling at the injection site. With GHK-Cu, a lot of people notice a brief burning sensation when they inject it. It doesn't usually last long, but it can be a bit uncomfortable, especially the first few times. Other mild side effects that sometimes get reported include fatigue, headache, or dizziness. Very rare, but worth mentioning. Typical Cycles A question I get all the time is: how long should I stay on GLOW therapy? This isn't meant to be taken nonstop forever. A common approach is a 4 to 12 week cycle, depending on your goals. After that, people usually take a break for 1 to 2 months to let the body reset.  For example, someone recovering from an injury might just do one cycle and be done, depending on the severity. While someone with chronic pain or inflammation (e.g., arthritis or degenerative disc disease, Crohn's) or someone using it for skin and anti-aging might do multiple cycles per year. It's really individualized. Who Should Avoid It So, who should not be on GLOW therapy? Because these peptides promote healing and blood vessel growth, anyone who is pregnant or breastfeeding or with a history of cancer should avoid GLOW therapy. And of course, if you've had any kind of allergic reaction to peptides before, that's a clear "no." Frequently Asked Questions Alright, let's wrap up with some FAQs because these usually come up. 1. How soon will I notice the results? It really depends on what you're targeting. For joint pain or muscle recovery, some people notice improvements within a week or two, especially if the inflammation is mild or the issue is more recent. More chronic or long-standing injuries can take a little longer. When it comes to skin and hair benefits from GHK-Cu, those changes usually take a couple of months to become noticeable, since collagen production and hair growth are naturally slower processes. 2. Do I have to stay on this forever? No, that's where cycling comes in. Most people use it for 4–12 weeks, then take a 1-2 month break. 3. Is GLOW only for athletes or injuries? Not at all. Athletes use it for recovery, but many people use it for gut health, skin rejuvenation, hair regrowth, or even surgical recovery. 4. Can I stack GLOW with other treatments? Yes, but it should be coordinated with your provider. It's often combined with hormone replacement therapy, PRP, or even cosmetic treatments, but the plan should be individualized. 5. Can I use GLOW peptides if I've had cancer in the past? Even after someone has been treated for cancer and is considered "cancer-free," not all cancer cells may be completely eliminated from the body. Some microscopic cells can remain dormant for months or even years. Because BPC-157 and TB-500 or TB4 promote tissue repair, cell growth, and new blood vessel formation, there's a theoretical risk that these dormant cells could be stimulated. That's why these peptides are generally avoided in anyone with a history of cancer unless a doctor has carefully reviewed the risks and given explicit clearance. Final thoughts So that's the full picture on GLOW peptide therapy. It's a blend designed to help your body heal, repair, and restore—whether that's from an injury, surgery, or just the natural wear and tear of life. And while the "glow" is real, it's not magic—it's science-driven, and it works best when used thoughtfully and safely. Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend—because we all could use a little GLOW up. Until next time, be well, and as always, have a happy, healthy week.
    --------  
    14:19

More Health & Wellness podcasts

About The Peptide Podcast

The Peptide Podcast makes health and wellness decisions SIMPLE, FAST, and FUN. In less than 15 minutes each weekday, you'll get accurate, unbiased updates on peptides—from disease prevention and performance health to anti-aging and more. Hosted by The Peptide Queen, a clinical pharmacist with more than 15 years of experience, the show cuts through internet confusion to give you clear, reliable information so you can choose what's best for you.
Podcast website

Listen to The Peptide Podcast, On Purpose with Jay Shetty and many other podcasts from around the world with the radio.net app

Get the free radio.net app

  • Stations and podcasts to bookmark
  • Stream via Wi-Fi or Bluetooth
  • Supports Carplay & Android Auto
  • Many other app features
Social
v7.23.11 | © 2007-2025 radio.de GmbH
Generated: 11/4/2025 - 5:48:58 AM